<DOC>
	<DOC>NCT00225693</DOC>
	<brief_summary>The study is intended to collect data to evaluate effectiveness and safety of drug eluting stent devices in a dose ranging assessment.</brief_summary>
	<brief_title>V-Flex Plus PTX Drug Eluting Coronary Stent</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. Patient must be an acceptable candidate for coronary artery bypass surgery Patient or legal guardian must have given informed consent Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status, an IVUS examination and a diagnostic angiogram. Patient must be less than 18 years old Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. Women of child bearing potential. Patient has other medical condition that any cause noncompliance with the protocol, confound the results or is associated with limited life expectancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>coronary artery</keyword>
	<keyword>restenosis</keyword>
	<keyword>patency</keyword>
	<keyword>drug eluting</keyword>
	<keyword>stent</keyword>
</DOC>